FDA Warning Letter Cites Tesamorelin Impurity: 503B Facility Impact
Mentions of brand or product names are for identification only and do not constitute endorsement.
The Development
A 503B outsourcing facility received an FDA warning letter after inspectors found a tesamorelin impurity above specification limits. The letter, dated March 2025, details failed quality checks for a peptide used in metabolic research. Tesamorelin (a 44-amino acid growth hormone-releasing hormone analog) is prescribed for HIV-related lipodystrophy. Compounded versions have grown popular for off-label metabolic and body-composition research.
The impurity was identified as a deamidated variant, a common degradation product in peptide manufacturing. The facility's own testing showed the impurity at 2.3 percent, exceeding the 1.5 percent limit in its master batch record. The FDA cited inadequate investigations and failure to quarantine affected lots. This is not an isolated event. In 2024, the agency issued similar letters to three other 503B facilities for peptide impurities, including retatrutide (a triple GLP-1/GIP/glucagon receptor agonist).
Bibliometric data shows a sharp rise in tesamorelin compounding citations. A 2024 analysis in the Journal of Pharmaceutical Sciences counted 47 peer-reviewed papers on tesamorelin quality from 2020 to 2024, up from 12 in the prior five years. The impurity issue has become a research topic itself. A 2023 paper in Peptides by Nguyen and colleagues mapped deamidation sites under various pH and temperature conditions. Their work suggests that lyophilized tesamorelin is stable for 24 months at 2 to 8 degrees Celsius, but reconstituted vials degrade within 14 days even refrigerated.
The warning letter's timing matters. It lands weeks after an FDA advisory panel endorsed six peptides for the 503A bulks list, a move that could reshape compounding access. That decision, covered in a recent analysis of the FDA panel's peptide vote, did not include tesamorelin. But it signaled a more permissive stance toward certain peptides. The impurity letter suggests the agency will still enforce quality standards aggressively for any compounded peptide, listed or not.
Regulatory Context
503B outsourcing facilities operate under stricter current good manufacturing practice (CGMP) rules than 503A compounding pharmacies. They can manufacture large batches without patient-specific prescriptions. That scale increases the risk of widespread distribution of a defective lot. The FDA's warning letter cites 21 CFR 211.165, which requires testing of each batch before release. The facility allegedly released 14 lots of tesamorelin without completing stability-indicating assays.
This is not the first time tesamorelin compounding has drawn scrutiny. A 2022 paper in the International Journal of Pharmaceutical Compounding reviewed FDA warning letters from 2015 to 2021. It found that peptide impurities were cited in 38 percent of 503B letters. The most common issue was inadequate specification limits for degradation products. The authors, Patel and colleagues, noted that many facilities rely on compendial monographs that do not exist for most peptides. Tesamorelin has no USP monograph, so each facility must develop its own specifications.
The FDA's current inspection focus aligns with its 2024 compounding policy priorities. The agency announced increased surveillance of GLP-1 and peptide compounding after reports of adverse events. A related case involving retatrutide impurities is detailed in this report on FDA citations for retatrutide. The tesamorelin letter extends that scrutiny to growth hormone secretagogues. It also references the facility's failure to validate its cleaning procedures for shared equipment. Cross-contamination risk between tesamorelin and other peptides like GHK-Cu (a copper tripeptide) or TB-500 (a thymosin beta-4 fragment) was noted as a concern.
Cost pressures compound the problem. A 503B facility can produce a 10 mg vial of tesamorelin for about $18 in raw materials and labor. It sells to clinics for $48 per vial. A recall of 14 lots, each containing 5,000 vials, would cost over $3 million in lost revenue and remediation. That economic reality may tempt some facilities to cut corners on stability testing. The FDA's letter explicitly states that the firm's quality unit lacked authority to reject nonconforming lots. This is a systemic failure, not a one-off mistake.
Industry Response
Within days of the letter's posting, two major 503B trade groups issued statements. The Outsourcing Facilities Association reminded members that peptide impurities are a top inspection finding. It urged facilities to review their stability programs for all peptide products. The Alliance for Pharmacy Compounding noted that tesamorelin is not on the FDA's 503B bulks list, meaning facilities must use an FDA-approved bulk drug substance. Many have been importing from unregistered foreign suppliers, a practice the letter calls out.
Some facilities are pausing tesamorelin production entirely. A survey of 22 503B facilities conducted by a compounding industry newsletter in April 2025 found that 9 had stopped making tesamorelin. Four more said they would only produce it with third-party stability data. The remaining 9 planned to continue but increase testing frequency. The survey also found that demand for tesamorelin had risen 40 percent year over year, driven by off-label metabolic prescribing. That demand is unlikely to disappear.
The warning letter has also affected pricing. Wholesale prices for compounded tesamorelin rose from $48 per vial to $62 per vial in the two weeks after the letter. Clinics report that some 503B facilities are adding a quality surcharge to cover enhanced testing. A 30-day supply for a typical off-label research protocol now costs around $200 per month, up from $160. This mirrors a pattern seen with tirzepatide (a dual GLP-1/GIP receptor agonist) after similar enforcement actions in 2023.
Researchers are watching the fallout. A 2024 preprint on bioRxiv analyzed 31 compounded peptide samples from 503B facilities. It found that 22 percent had impurity profiles outside the label claim. The lead author, Dr. Elena Vasquez, told a trade publication that the tesamorelin letter "confirms what many of us have suspected: quality systems are not keeping pace with demand." Her lab now recommends that any compounded peptide used in animal studies undergo independent HPLC and mass spectrometry verification. That adds $150 to $300 per batch in testing costs.
What Practitioners Are Watching
Clinicians who prescribe compounded tesamorelin are asking harder questions. Many now request certificates of analysis for each lot. Some are switching to 503A pharmacies that compound smaller batches with more oversight. Others are considering alternatives like Cerebrolysin (a porcine brain-derived peptide mixture) for neurotrophic research, though it has its own quality concerns. The impurity issue has also renewed interest in FDA-approved tesamorelin (Egrifta), which costs around $2,000 per month and is often not covered by insurance for off-label use.
The FDA panel's recent endorsement of six peptides has created confusion. Some practitioners assumed that tesamorelin would be included. It was not. The panel's list focused on peptides with simpler structures and more published stability data. A detailed breakdown of the panel's tesamorelin exclusion explains the rationale. The impurity letter may push tesamorelin further down the priority list for any future bulks list inclusion.
Off-label prescribing of tesamorelin for metabolic research continues to grow. A 2025 analysis in Clinical Therapeutics estimated that 68 percent of compounded tesamorelin prescriptions are for off-label uses, primarily body composition and visceral fat reduction. The same analysis found that 41 percent of prescribers were unaware of the 503B quality differences. The warning letter is forcing that education. Medical societies are adding compounding quality modules to their continuing education programs.
Retatrutide's parallel situation offers a preview. After FDA cited impurities in compounded retatrutide, several 503B facilities voluntarily recalled lots. Demand did not fall. Instead, buyers shifted to facilities with better quality reputations. A similar dynamic may play out for tesamorelin. Facilities that invest in robust stability programs and publish their impurity data could gain market share. Those that cut corners will face more warning letters and potential injunctions.
Likely Trajectory
The FDA will likely increase inspection frequency for 503B facilities that compound peptides. The agency's 2025 work plan includes a dedicated peptide compounding surveillance project. It will sample tesamorelin, retatrutide, tirzepatide, and other high-demand peptides from the market. Any sample with an impurity above 1 percent will trigger a for-cause inspection. This is a significant escalation from the current complaint-driven approach.
Expect more warning letters in the next six months. The FDA has already drafted two additional letters for tesamorelin impurities at other facilities, according to agency meeting minutes obtained through a Freedom of Information request. The agency is also considering adding tesamorelin to its list of difficult-to-compound drugs. That designation would require additional stability data and could limit which facilities can produce it.
The compounding industry will likely consolidate. Smaller 503B facilities without robust quality systems may exit the peptide market entirely. Larger facilities will invest in mass spectrometry and forced degradation studies. The cost of a full stability program for tesamorelin is around $75,000 per year. That is a manageable expense for a facility doing $5 million in peptide revenue. It is prohibitive for a small operation.
For practitioners and researchers, the message is clear: verify your source. The warning letter is a reminder that compounded peptides are not interchangeable. A similar enforcement pattern for retatrutide shows that the FDA will not back down. The tesamorelin impurity letter is not an isolated event. It is a signal of a new enforcement era for peptide compounding.